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Cationic liposomes are widely used to facilitate introduction of genetic material into target
cells during transfection. This study describes a non-receptor mediated herpes simplex
virus type-1 (HSV-1) entry into the Chinese hamster ovary (CHO-K1) cells that naturally
lack glycoprotein D (gD)-receptors using a commercially available cationic liposome:
lipofectamine. Presence of cell surface heparan sulfate (HS) increased the levels of viral
entry indicating a potential role of HS in this mode of entry. Loss of viral entry in the
presence of actin de-polymerizing or lysosomotropic agents suggests that this mode
of entry results in the endocytosis of the lipofectamine-virus mixture. Enhancement of
HSV-1 entry by liposomes was also demonstrated in vivo using a zebrafish embryomodel
that showed stronger infection in the eyes and other tissues. Our study provides novel
insights into gD receptor independent viral entry pathways and can guide new strategies
to enhance the delivery of viral gene therapy vectors or oncolytic viruses.
Keywords: heparan sulfate, virus-cell interactions, viral entry
INTRODUCTION
HSV-1 is prevalent pathogen in various clinical manifestations ranging from common cold
sore, gingivostomatitis, herpetic whitlow, corneal herpetic stromal keratitis, genital ulcers, and
sometimesmore serious complications such as encephalitis andmeningitis (Nahmias and Roizman,
1973; Whitley et al., 1998; Whitley and Roizman, 2001). The current model of HSV entry suggests
that the virus uses multiple pathways during entry depending on cell types and entry receptors
(Spear and Longnecker, 2003; Karasneh and Shukla, 2011; Salameh et al., 2012). HSV-1 entry
generally begins with viral attachment to host cells in which HSV glycoproteins B (gB) and C (gC)
on the envelope of the virus typically bind to heparan sulfate (HS) on the surface of the host cell
(WuDunn and Spear, 1989; Herold et al., 1991; Shieh et al., 1992). This is followed by gD binding
to one of its cognate receptors including an intercellular adhesion molecule: nectin −1 or −2
(Geraghty et al., 1998) and amember of the tumor necrosis factor receptor family: herpesvirus entry
mediator (HVEM; Montgomery et al., 1996). The virus also uses a modified version of HS known
as 3-O sulfated heparan sulfate (3-OS HS) to bind gD and induce virus cell fusion independent of
the known protein receptors (Shukla et al., 1999; Shukla and Spear, 2001). Viral interactions with
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these receptors initiate fusion between the viral envelope and
the membrane of the cell, which also requires participation of
two additional HSV glycoproteins gH and gL (Pertel et al., 2001;
Spear and Longnecker, 2003). Upon fusion, the nucleocapsid
and tegument are released into the cytoplasm where they are
transported to the nucleus viamicrotubules. Our previous studies
have shown that HSV entry exploits host cell cytoskeleton via a
novel phagocytic uptake in human corneal fibroblasts (CF) cells
and that modified 3-OS HS plays a significant role in promoting
viral entry and spread via F-actin membrane extensions such as
filopodia (Clement et al., 2006; Oh et al., 2010; Choudhary et al.,
2013).
Because HSV depends on a receptor-mediated entry, CHO
cells that naturally lack gD receptors and hence resistant to
HSV infections (Montgomery et al., 1996), are a well-known
model to study receptor-independent entry of HSV. To make
them susceptible, these cells need to be transfected with one of
the gD receptors. During one of our transfection experiments,
we accidently infected CHO-K1 cells lacking gD receptors with
HSV-1 in the presence of cell transfection reagent, Lipofectamine
2000. To our surprise we observed robust viral entry. This was
interesting as virus entry was observed in the absence of any
gD receptors. Based on this finding, our study investigates a
non-receptor mediated HSV entry. It demonstrates a role for
HS and the cytoskeleton filaments in gD receptor-independent
endocytosis of HSV into naturally resistant CHO-K1 cells.
Overall, we provide a new understanding of gD receptor-
independent viral entry mechanisms and help generate a new
strategy to enhance the delivery of viral gene therapy vectors.
MATERIALS AND METHODS
Western University of Health Sciences (WUHS) Institutional
Animal Care and Use Committee specifically approved this study
(IACUC protocol number 026).
Cell Culture and Viruses
Wild-type Chinese hamster ovarian-K1 (CHO-K1), reporter
CHO-Ig8 cells that expresses β-galactosidase upon viral
entry (Montgomery et al., 1996), CHO-745 that lack
glycosaminoglycans including HS (WuDunn and Spear,
1989), Vero, HeLa, and primary cultures of human corneal
fibroblasts (CF) cells (Clement et al., 2006) were used in this
study. The CF was procured from corneal tissue purchased from
Illinois eye bank. www.eversightvision.org/illinois/. All CHO
cells were grown in Ham’s F-12 medium (Gibco/BRL, Carlsbad,
CA, USA) supplemented with 10% fetal bovine serum (FBS)
and 1% penicillin and streptomycin (P/S, Gibco/BRL). Vero and
HeLa cells were grown in Dulbecco’s modified Eagle’s medium
(DMEM) supplemented with 10% FBS and P/S. Primary cultures
of human CF were maintained as previously described. The
β-galactosidase expressing recombinant HSV-1 (KOS) gL86
and GFP-expressing HSV-1 (K26GFP) were provided by P.G.
Spear (Northwestern University, Chicago) and P. Desai (Johns
Hopkins University; Desai and Person, 1998). The HSV-1 gL86
is a recombinant virus in which a portion of the “gL” gene was
replaced with the lac Z gene encoding for the β-galactosidase
enzyme (Montgomery et al., 1996). Only upon entry and
successful infection, the β-galactosidase enzyme is synthesized
and activated. Thus, the activity of this enzyme, using a substrate
like ONPG, is measured as an indicator of viral entry. In our
experiments the enzymatic activity was measured as optical
density (OD) at 410 nm by a spectrophotometer.
HSV-1 Viral Entry Assay
CHO-K1, cells were grown in 96 or 6 well-plates to subconfluence
and infected with β-galactosidase expressing recombinant gL86
100 pfu/cell using Lipofectamine 2000 (Invitrogen). Uninfected
cells in the presence and absence of lipofectamine were used as
negative controls. Six hours post-infection (hpi), β-galactosidase
assays were performed using o-nitrophenyl-D-galactopyranoside
(ImmunoPure ONPG; Pierce) or 5-bromo-4-chloro-3-indolyl-_-
D-galactopyranoside (X-gal; Sigma). For the soluble substrate,
the enzymatic activity was measured at 410 nm using a micro-
plate reader (Molecular Devices spectra MAX 190, Sunnyvale,
CA). For X-gal assay, the cells were fixed (2% formaldehyde and
0.2% glutaraldehyde) and permeabilized (2 mM MgCl2, 0.01%
deoxycholate, and 0.02% nonidet NP-40 Sigma). Finally, 1mL of
β-galactosidase reagent (1.0 mg/mL X-gal in ferricyanide buffer)
was added to each well and incubated at 37◦C for 90 min before
the cells were examined using brightfield microscopy under the
20× objectives (Nikon D-Eclipse-C1). Similar experiments were
performed using β-galactosidase expressing CHO-Ig8 cells.
Immunofluorescence Imaging
Cultured monolayers of human corneal fibroblasts (CF) were
infected with HSV-1 K26GFP at 50 PFU in serum free media
Opti-MEM, and this was followed by fixation of cells at 1 h
post-infection using fixative buffer (2% formaldehyde and 0.2%
glutaradehyde). The cells were then washed with NaCl/Pi and
permeabilized with 2mMMgCl2, 0.01% deoxycholate, and 0.02%
Nonidet NP-40 for 20 min. After rinsing with NaCl/Pi, 10
nM rhodamine-conjugated phalloidin (Invitrogen) was added
for F-actin staining at room temperature for 45 min. Finally,
the cells were washed three times with one NaCl/Pi. Images
of immunofluorescent labeled cells were acquired by using a
confocal microscope (Nikon D-Eclipse-C1) using the software
EZ-C1.
Scanning Electron Microscopy (SEM)
Wild-type CHO-K1 and CHO-745 cells were grown in 60 mm
plates and infected with HSV-1 (KOS) at 50 pfu/cell for 0, 30,
and 60 min at 37◦C. Uninfected cells in the presence and absence
of lipofectamine were used as negative controls. The cells were
then fixed with 2% formaldehyde/ 4% glutaraldehyde in 1 ×
Dulbecco’s phosphate buffer saline (PBS) prior to SEM study.
This was followed by fixing cells with 1% osmium tetroxide
for 40 min. Dehydration was done in an increasing order (25–
100%) of ethanol treatment at 5 min each, respectively. Hundred
percentage ethanol was repeated to ensure dehydration. Cover
slips were removed from dishes and mounted on aluminum
studs previously cleaned with 100% ethanol. Cover slip edges
were painted with colloidal silver for conduction and dried in a
Critical Point Dryer (Samdri-780A). Samples were then coated
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with gold using a Sputter Coater (Hummer VI-A) for 2 min.
Samples were viewed using a Hitachi S-2700 Scanning Electron
Microscope (SEM). Images were captured at 1000–5000x using
4Pi Revolution image capture system.
Western Blots
Heparan sulfate (HS) positive CHO-K1 and HS negative
CHO-745 cells were infected for 3 h at 37◦C with HSV-1 gL86
virus at 10 PFU/cell in presence and absence of lipofectamine
(8 µg/mL). Cells were lysed in radioimmunoprecipitation
buffer (RIPA, Sigma) with Proteinase and Phosphatase
(Halt, Pierce Biotechnology) and electrophoresed on a 4–
12% Bis-Tris Gel (NuPage). A PVDF membrane (Novex)
was used for transfer. After initial non-specific blocking in
5% non-fat milk, the membrane was then incubated with
primary (VP16 mouse monoclonal, Santa Cruz; GAPDH
rabbit polyclonal, Santa Cruz) and secondary HRP-conjugated
antibodies (Jackson). The membrane was then developed
(ECL, Pierce) and visualized (ImageQuant LAS 4000, GE
Healthcare).
Zebrafish Experiments
Usage of Zebrafish (ZF) embryo experiment was conducted
under approved protocol (IACUC/026) by WUHS, Pomona,
California. WIK strain of 1 day old Zebrafish embryos
were obtained from ZFIN. On day 3 the zebrafish embryos
were infected with a mixture containing 108 HSV in 10
µg/mL lipofectamine (10 µg/mL) in 96 well-dishes. In parallel
experiments, zebrafish embryos were pre-treated with heparinase
I and II (1U/ml for 5 h) or mock treated before HSV-1
infection. Addition of the soluble substrate [o-nitrophenyl-β-D-
galactopyranoside (ONPG, ImmunoPure, Pierce; 3 mg/ml)] in
the culture medium followed by fluorescence measurement led
to the generation of dose–response curves for HSV-1 infected
zebrafish embryos. The enzymatic activity was measured at 410
nm using a micro-plate reader. For X-gal assay, after 24 h post-
infection, the embryos were fixed (2% formaldehyde and 0.2%
glutaraldehyde) overnight at 4◦C, permeabilized (2 mM MgCl2,
0.01% deoxycholate, and 0.02% nonidet NP-40 (Sigma) for 8 h at
4◦C and then 1 mg/mL X-gal in ferricyanide buffer was added to
the embryos and left overnight at 37◦C. The embryos were then
imaged the next day.
Statistics
The data presented in each experiment are the means of
triplicate measures and are representative of three independent
experiments. Significant differences were calculated using t-test
(Analysis of Variance). P < 0.05 was considered statistically
significant.
RESULTS
HSV-1 Entry Is Enhanced by Lipofectamine
in the Absence of Glycoprotein D (gD)
Receptors and Is Viral Strain Independent
In order to confirm that lipofectamine helps facilitate HSV-
1 infection, an entry assay was performed using the resistant
CHO-K1 cell line (Montgomery et al., 1996). We used
commercially available cationic liposome (Lipofectamine 2000)
in our experiments. HSV-1 entry into the cells was determined
by using β-galactosidase expressing HSV-1 reporter virus (gL86).
Expression levels of β-galactosidase are induced byHSV infection
and therefore it can be used as a measureable indicator of viral
entry (Montgomery et al., 1996). Quantification and visualization
of β-galactosidase levels by using two different substrates:
ONPG and X-gal, show that HSV-1 gL86 pre-incubation with
lipofectamine (L) resulted in higher levels of HSV-1 entry in
receptor (R) negative CHO-K1 cells (Figures 1A,B). Similarly,
enhanced viral entry was also noted in wild-type CHO-K1 cells
when Green fluorescent protein (GFP)-tagged HSV-1 virions
(K26GFP; Desai and Person, 1998) was in a mixture with
lipofectamine (Figure 1C). To check if non-receptor mediated
viral entry is HSV strain dependent, we tested the ability of
lipofectamine to enhance viral entry of different strains of HSV-
1/-2 (F, G, MP, and 17 strains). Here we used CHO Ig8 cells
that express β-galactosidase upon viral entry (Montgomery et al.,
1996). The HSV strains were pre-incubated with lipofectamine
and subsequently infection was performed. The results from
this experiment showed that lipofectamine enhanced entry of
different HSV strains in a dosage dependent manner as evident
by ONPG assay (Figure 1D). It has been previously shown that
liposome encapsulation of retrovirus and hepatitis D virus allows
efficient infection in resistant cell lines (Innes et al., 1990; Bichko
et al., 1994). A similar effect is likely seen with lipofectamine/HSV
mixture.
Presence of Lipofectamine-HSV-1 Mixture
Further Enhances Entry in Natural Target
Cells
We next evaluated the ability of lipofectamine to enhance
HSV-1 entry into naturally permissive or target cell lines.
Confluent monolayers of HeLa, Vero, and primary cultures
of human CF were plated and infected with HSV-1(gL86)
in the presence and absence of lipofectamine and the entry
of HSV-1 were measured using the assay mentioned above.
β-galactosidase expression levels were higher in the cells that
were treated with lipofectamine (black bar) than the parallel
untreated control (white bar). The entry was not significantly
higher as HeLa, Vero, and CF are known to express gD
receptors and are already highly susceptible to HSV-1 infection
(Tiwari et al., 2006; Figure 2A). In order to obtain more direct
and visual evidence of lipofectamine-mediated HSV-1 entry
in CF cells, K26GFP was pre-incubated with lipofectamine to
infect cultured CF, and fluorescence microscopy was used to
visualize the virions (Figure 2B). The GFP-punctate dots with
high intensity were noticed when HSV-1 was allowed to infect
in the presence of lipofectamine (Figure 2Bc), compared to
GFP-HSV-1 in the absence of lipofectamine (Figure 2Bb). This
suggests that lipofectamine-virus mixture were equally effective
in delivering HSV-1 into susceptible cells expressing gD receptors
and the system of introducing lipofectamine-virus mixture into
susceptible cells were not interfered by the presence of gD
receptors.
Frontiers in Microbiology | www.frontiersin.org 3 June 2016 | Volume 7 | Article 973
Burnham et al. HSV Entry in Presence of Lipofectamine
Lipofectamine-HSV-1 Mixture Mediated
Entry is Concentration Dependent
To quantitatively demonstrate the effectiveness of lipofectamine
in allowing HSV-1 entry into resistant CHO-K1 cells, we
incubated different concentrations (from 1.0–8.0 µg/mL) of
lipofectamine with gL86 for 15 min at room temperature. The
PBS treated gL86 was considered as a control for comparison.
Maximum viral entry, via ONPG and X-gal assays, was
detected at a higher concentration (8.0 µg/mL) of lipofectamine
(Figures 2C,Dd). Again, HSV-1 without lipofectamine failed to
infect CHO-K1 cells (Figure 2Da). Similar concentration (8.0–10
µg/mL) of lipofectamine has been reported to mediate ecotropic
murine leukemia virus and hepatitis D virus infections (Innes
et al., 1990; Bichko et al., 1994).
Cell Surface Heparan Sulfate Plays a
Critical Role during
Lipofectamine-Mediated
gD-Receptor-Independent HSV-1 Entry
We further probed the mechanism non-receptor mediated entry
by investigating the role of cell surface HS which are highly
expressed on CHO-K1 cells. It is well-documented that HS is a
negatively charged cell surface attachment receptor that virtually
FIGURE 1 | Lipofectamine-HSV-1 entry into receptor negative CHO-K1 cells. (A) ONPG virus entry in CHO-K1 cells infected with gL86 in the presence (+) and
absence (–) of lipofectamine (4 µg/mL) quantified at 6hpi. (B) Stained images of X-gal in CHO-K1 cells infected with gL86 in the presence (+, panel c) and absence (–,
panel b) of lipofectamine (4 µg/mL). (C) Wild type CHO-K1 cells were infected with K26-GFP with and without lipofectamine (4 µg/mL) and fluorescence intensity was
quantified 3hpi. Asterisks indicate significant difference from the uninfected control (P < 0.05, t-test); error bars represent SD (n = 4). (D) 3-OST-3 isoform expressing
CHO Ig8 cells were infected with the indicated strains in the presence (bars with cross line) and absence (plain bars) of lipofectamine and virus entry was measured by
ONPG. The data shown are the means of triplicate measures and are representative of three independent experiments. Asterisks indicate significant difference from
the uninfected control (P < 0.05, t-test); error bars represent SD (n = 3). L, Lipofectamine; R, Receptor.
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FIGURE 2 | Enhanced effect on HSV-1 entry in naturally susceptible cells in the presence of lipofectamine. (A) The indicated cells were plated in 96
well-plates and infected with gL86 virus in the presence (black bars) and absence of (white bars) lipofectamine. The viral entry was measured by ONPG assay 6hpi. L,
Lipofectamine (B) Human CF, stained with actin (shown as red), was infected with K26-GFP in the presence (panel c) and absence (panel b) of lipofectamine.
Uninfected and lipofectamine untreated CF served as negative control (panel a). The boxed regions in panel a–c are highlighted as a1–c1. The data shown are the
means of triplicate measures and are representative of three independent experiments. (C) Lipofectamine concentration dictates HSV-1 entry. CHO-K1 cells in 96
well-plates were infected with gL86 along with the indicated concentrations of lipofectamine. Entry was quantified 6hpi by ONPG assay. Asterisks indicate significant
difference from the uninfected control (P < 0.05, t-test); error bars represent SD (n = 3). (D) Virus entry by X-gal assay in CHO-K1 cells infected with gL86 with 2
µg/mL (panel b), 4 µg/mL (panel c), and 8 µg/mL (panel d) of lipofectamine and without lipofectamine (panel a). The data shown are the means of triplicate measures
and are representative of three independent experiments.
all human herpesviruses recognize during initial attachment
to cells (Shukla and Spear, 2001) and has a role in disease
manifestations (Ferro, 2013). The significance of HS in absence of
gD receptor is well-recognized as CHO-K1 cells allow sufficient
viral binding/attachment but not entry because of lack of gD-
receptor, while CHO mutant cells defective in HS biosynthesis
(CHO-745) do not allow viral binding or attachment (Shukla
et al., 1999). To determine whether presence of anionic HS assists
the delivery of cationic lipofectamine-virus mixture into cells,
we infected both CHO-K1 and CHO-745 cells with HSV-1 in
the presence and absence of lipofectamine. The untreated HSV-
1 was kept as negative control for both types of cells. Entry
was quantified by ONPG assay and the levels of viral tegument
protein: VP16 (Heine et al., 1974; Weinheimer et al., 1992) was
assessed by western blot. Lipofectamine mediated HSV entry was
prominent in wild-type CHO-K1 cell but not in CHO-745 cells
(Figures 3A,B) suggesting the role of HS involved in viral entry
mediated by lipofectamine.
To further verify whether lipofectamine mediated entry was
HS-dependent, high resolution scanning electron microscopy
(SEM) was performed. HS expressing wild-type CHO-K1 cells
and HS deficient CHO-745 cells were infected with HSV-
1 in the presence of lipofectamine and processed for SEM.
The SEM images demonstrated the presence of large numbers
of virus particles attached to F-actin membrane structures
including filopodia, which are induced upon infection and
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FIGURE 3 | Significance of heparan sulfate (HS) in lipofectamine mediated HSV-1 uptake. (A) Virus entry in CHO-K1 and HS deficient CHO-745 cells infected
with gL86 in the presence and absence of lipofectamine (4 µg/mL) was determined by ONPG. Asterisks indicate significant difference from the CHO-K1 cells infected
in absence of lipofectamine (P < 0.05, t-test); error bars represent SD (n = 3). While CHO-745 cells infected with HSV-1 in presence and absence of lipofecatine had
no significant differences. (B) VP-16 levels compared between CHO-K1 and HS negative (CHO-745) cells via western blot (L, Lipofectamine; R, Receptor). (C).
Scanning electron microscopy (SEM) performed on CHO-K1 cells infected with HSV-1 along with lipofectamine shows filiopodia (panel a) and HSV-1 uptake (panel b),
while HSV-1 without lipofectamine infected cells show smooth surface (panel c). The boxed regions in panel a–c are highlighted as a1–c1. In parallel lipofectamine
mixture with HSV-1 had little or no actin cytoskeleton activity in CHO-745 cells (panel a,b). Similarly no filopodia were noticed in HSV-1 infected CHO-745 cells in
absence of lipofectamine (panel c). The boxed regions in panel a–c are highlighted as a1–c1. The data shown are the means of triplicate measures and are
representative of three independent experiments. (D) Host cell cytoskeleton is critical during uptake of lipofectamine-HSV-1 mixture in absence of gD receptors. (D)
Panel a: Cultured monolayers of CHO-K1 cells were pre-treated with the 0.5 µg/mL actin depolymerizing agent Cytochalisin D (Cyto D; panel a) before infecting with
gL86 along with lipofectamine. Cells treated with 1 × PBS treated cells were used as a control. Viral entry was measure by ONPG assay. Panel b: Cells were
pre-treated with 0.02 µM Bafilomycin A1 (BFLA-1) and then infected with gL86. Viral entry was measured using ONPG assay. The data shown are the means of
triplicate measures and are representative of three independent experiments. Asterisks indicate significant difference from the Cyto-D/BFLA-1 treated control (P <
0.05, t-test); error bars represent SD (n = 3).
Frontiers in Microbiology | www.frontiersin.org 6 June 2016 | Volume 7 | Article 973
Burnham et al. HSV Entry in Presence of Lipofectamine
express higher amounts of HS (Oh et al., 2010; Figures 3Ca,Cb),
while uninfected CHO-K1 cells had a relatively smooth surface
(Figure 3Cc). In contrast, virus-lipofectamine mixture were
adhered and clumped on the cell membrane of CHO-745 cells
(Figures 3Cb,Cc) as no or very little outgrowth of filopodia
was noticed in both infected and uninfected CHO-745 cells
(Figure 3Ca). These results show that HS may play a significant
role in HSV-1 entry in the absence of gD-receptor.
Endocytosis of Lipofectamine-Virus
Mixture during Entry Exploits
Actin-Cytoskeleton Including Filopodia
As lipofectamine and HSV mainly enter cells by endocytosis
(Nicola et al., 2003; Cui et al., 2012), we speculated that the
lipofectamine-HSV mixture is also being endocytosed. It has
been reported that HSV entry through endocytosis leads to a
change in arrangement of cytoskeleton elements (Lyman and
Enquist, 2009). As discussed above, we found enhancement of
filopodia formation and the presence of virions on the filopodia
from SEM imaging in CHO-K1 cells. Based on this observation,
we predicted that actin filaments can be beneficial to non-
receptor mediated entry. To demonstrate this, viral entry assay
was performed in the presence of an F-actin depolymerizer.
CHO-K1 cells were pre-treated with Cytochalasin D (Cyto D)
prior to infection. It was postulated that pre-treatment of Cyto-
D would have more negative effect provided the actin-based
membrane protrusions (such as filopodia) played a role in
the attachment and entry of lipofectamine-virus mixture. As
predicted, actin depolymerizing agent Cyto-D negatively affected
virus entry (Figure 3D, Top panel). The expected loss of filopodia
due to Cyto-D treatment in these experiments correlates well
to our prior knowledge that filopodia plays a significant role
during HSV-1 entry (Oh et al., 2010). Next, we examined the
role of pH dependence in non-receptor mediated entry. The
rationale was based on the fact that lipofectamine-virus mixture
might be taken in an endosomal vesicle which has an acidic
pH (Geisow and Evans, 1984). Thus, effects of lysosomotropic
agent (bafilomycin A1; BFLA-1) that are capable of interfering
with vesicular acidification (Lukacs et al., 1990) were tested
for their effects on virus entry. Lipofectamine-virus mixture
showed significantly low viral entry in the presence of BFLA-1
reinforcing the point that pH plays an important role in non-
receptor mediated virus entry (Figure 3Db). Taken together, it
can be implied that lipofectamine-virus mixture enters through
endocytosis and depends on actin filaments for the uptake and
low pH for a successful entry.
Lipofectamine-Virus Mixture Promotes
HSV Infection in Zebrafish Embryo Model
Finally, we tested the in vivo significance of lipofectamine-virus
mixture in a Zebrafish (ZF) infection model (Burgos et al., 2008).
Using 3 day old ZF embryos, HSV-1 infection with and without
lipofectamine was performed. HSV entry in ZF embryos were
assessed by ONPG and X-gal assays after 18 h post-infection.
A high intensity blue staining of ZF embryos were observed
in virus-lipofectamine treated group compared to virus alone
infected embryos (Figures 4Ab,Ac) indicating that more virus
has entered. The mock infected ZF embryo remained colorless
following X gal staining (Figure 4Aa). A similar pattern of HSV
entry was observed and quantified in zebrafish embryos by
ONPG assay (Figure 4B). Interestingly, pre-treatment of ZF-
embryos with heparinase I and II (1 U/mL) reduces lipofectamine
mediated virus HSV-1 entry (Figure 4C). Thus, it was clear that
lipofectamine-mediated virus infection can be achieved in live
animal models.
DISCUSSION
To summarize, our study, for the first time, describes how HSV-1
gets into cells by a non-receptor mediated endocytosis, meaning
that virus entry and infection can occur without the presence
of gD receptors. Receptor mediated endocytosis requires the
presence of at least one of the gD receptors (Shukla and Spear,
2001) for viral entry and infection to occur. However, using
a lipofectamine-virus mixture, we show that in gD receptor
lacking CHO-K1 cells, the virus can successfully enter and infect
without the need of gD receptors (Figure 1). We compared this
mode of entry in natural target cells such as HeLa and primary
corneal fibroblasts. Though entry levels were not significant (as
these cells naturally express gD receptors), higher entry levels
in the presence of lipofectamine were observed consistently in
all natural target cells (Figure 2). Also, the presence of natural
gD receptors in these cells did not interfere with the entry
of lipofectamine-virus mixture suggesting that HSV-1 entry in
the presence of lipofectamine can still use gD receptors. We
also found that lipofectamine-virus mixture is not virus strain
dependent (Figure 1D), and can be used to enhance entry in live
animal models, suggesting the universal nature of lipofectamine-
mediated entry.
Previous studies show the importance of the rearrangement
of cytoskeleton elements and pH dependence for endocytosis
(Nicola et al., 2003; Lyman and Enquist, 2009; Cui et al.,
2012). Keeping this into consideration, we show that non-
receptor mediated entry requires actin filaments and low pH
for a successful HSV-1 entry and blocking either one of these
factors results in loss of viral entry indicating that lipofectamine-
HSV mixture uses endocytosis as a mode of entry. However,
an intriguing question arises at this point: if the virus does
not use gD receptor, how does it lose its coat proteins, get
endocytosed and become infectious? One of the plausible
assumptions could be that low pH of endosomes may play a
role in the virus becoming infectious. Low pH is known to bring
about conformational changes in glycoprotein B (gB), which
are much favorable for fusion with a vesicular membrane and
may not require a gD receptor (Dollery et al., 2010). More
specifically, some gB receptors such as non-muscle myosin IIA
could facilitate the process (Arii et al., 2010). It is also possible
that lipofectamine by its membrane permeability property may
itself expose the fusogenic domain of gB without requiring
the gD/receptor mixture to trigger the process. This mixture
could thus be potentially used for delivering a gD null virus for
vaccine development and functional studies. Future studies will
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FIGURE 4 | Significance of lipofectamine HSV-1 mixture uptake in Zebrafish embryo model. WIK strain of 3 day old Zebrafish embryo was infected with 108
HSV in presence (panel c) and absence (panel b) of lipofectamine (10 µg/mL). (A) shows 24hpi X gal staining in Zebrafish embryos, while (B) indicates ONPG assay
conducted with Zebrafish embryos in the presence and absence of lipofectamine. Asterisks indicate significant difference from the uninfected control (P < 0.05,
t-test); error bars represent SD (n = 3). L: Lipofectamine. (C): pre-treatment of Zebrafish embryos with heparinase I and II (1U/ml) reduce lipofectamine (L) mediated
HSV-1 entry compare to heparinase untreated embryos. Reporter virus based HSV-1 entry assay was conducted by using ONPG assay. The data shown are the
means of triplicate measures and are representative of three independent experiments. Asterisks indicate significant difference from the heparinase untreated control
(P < 0.05, t-test); error bars represent SD (n = 3).
determine the exact mechanism by which the capsid is released
into the cytosol.
There is enough evidence to suggest that HS plays an
important role in HSV pathogenesis (Shukla and Spear, 2001).
In this study we demonstrated a novel role that HS plays in
non-receptor mediated entry. The presence of HS on cell surface
clearly enhances entry (Figure 3). The need for HS could be
crucial for Lipofectamine-virus delivery due to fact that HS
is negatively charged and may directly interact with cationic
liposomes. Entry into animal models such as ZF also requires HS
(Antoine et al., 2014) and therefore, the fact that Lipofectamine
enhances entry in vivo could be used to identify the tissues
which may be more susceptible due to the presence of HS. While
zebrafish has been shown to support entry of HSV and other
viruses, more tedious ways such as microinjection is normally
required to initiate viral entry in this model (Burgos et al.,
2008; Antoine et al., 2014). Our study also demonstrates a
much easier way to facilitate HSV-1 entry in zebrafish (Figure 4)
and does not require sophisticated microinjection equipment.
Interestingly, we observed a higher X-gal staining in the eye and
other tissues in the virus-lipofectamine treated group compared
to virus alone infected embryos (data not shown). Although
more studies are needed to outline the actual mechanism by
which lipofectamine-virus mixture is entering and infecting cells
and how the diversity of HS proteoglycans can affect this, our
demonstration of the HSV uptake in the absence of gD receptors
has given a platform to look beyond the role of gD receptors
and discover new receptors or components and learn about
their role in viral entry and transport. In addition, because
the roles of gD in nuclear viral egress (Johnson and Baines,
2011; Johnson et al., 2011) and cell-to-cell spread (Pertel et al.,
2001; Akhtar and Shukla, 2009; Karasneh and Shukla, 2011)
are well-established, the lipofectamine-virus mixture may be
utilized to shed light on the possible roles of gD receptors
in the above mentioned events. Further, role of other HSV-
1 glycoproteins such as gK which is known to be involved
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in virus spread and alterations in viral receptor expression in
the eye (Allen et al., 2014), needs to be investigated during
HSV-1-liposome mixture mediated infection in zebrafish ocular
model.
AUTHOR CONTRIBUTIONS
LB and DJ equally contributed to the work. KJ and VT did the
zebrafish experiments. LB and JT did the Electron Microscopy
studies. VT designed the study and analyzed the data. DJ, DS,
and VT wrote the manuscript. LB, JT, DJ, DS, KJ, and VT read,
corrected and approved the final manuscript.
FUNDING
This investigation was supported by internal Instructional
grant support (grant number N12587) to VT from WUHS,
Pomona, CA, and grants from National Institutes of Health 1R15
AI088429-01A1 and R21 AI105573.
ACKNOWLEDGMENTS
We sincerely acknowledge the facility at California State
University, San Bernardino for EM imaging. Usage of Zebrafish
embryo experiment was conducted under Western University of
Health Sciences (WUHS) protocol IACUC/026.
REFERENCES
Akhtar, J., and Shukla, D. (2009). Viral entry mechanisms: cellular and viral
mediators of herpes simplex virus entry. FEBS J. 276, 7228–7236. doi:
10.1111/j.1742-4658.2009.07402.x
Allen, S. J., Mott, K. R., and Ghiasi, H. (2014). Overexpression of herpes simplex
virus glycoprotein K (gK) alters expression of HSV receptors in ocularly-
infected mice. Invest. Ophthalmol. Vis. Sci. 55, 2442–2451. doi: 10.1167/iovs.14-
14013
Antoine, T. E., Jones, K. S., Dale, M. R., Shukla, D., and Tiwari, V. (2014).
Zebrafish: modeling for herpes simplex virus infections. Zebrafish 11, 17–25.
doi: 10.1089/zeb.2013.0920
Arii, J., Goto, H., Suenaga, T., Oyama, M., Kozuka-Hata, H., Imai, T.,
et al. (2010). Non-muscle myosin IIA is a functional entry receptor
for herpes simplex virus-1. Nature 467, 859–864. doi: 10.1038/nature
09420
Bichko, V., Netter, H. J., and Taylor, J. (1994). Introduction of hepatitis delta virus
into animal cell lines via cationic liposomes. J. Virol. 68, 5247–5252.
Burgos, J. S., Ripoll-Gomez, J., Alfaro, J. M., Sastre, I., and Valdivieso, F. (2008).
Zebrafish as a new model for herpes simplex virus type 1 infection. Zebrafish 5,
323–333. doi: 10.1089/zeb.2008.0552
Choudhary, S., Burnham, L., Thompson, J. M., Shukla, D., and Tiwari, V.
(2013). Role of filopodia in HSV-1 entry into zebrafish 3-O-sulfotransferase-
3-expressing cells. Open Virol. J. 7, 41–48. doi: 10.2174/18743579013070
10041
Clement, C., Tiwari, V., Scanlan, P. M., Valyi-Nagy, T., Yue, B. Y., and Shukla, D.
A. (2006). novel role for phagocytosis-like uptake in herpes simplex virus entry.
J. Cell Biol. 174, 1009–1021. doi: 10.1083/jcb.200509155
Cui, S., Wang, B., Zhao, Y., Chen, H., Ding, H., Zhi, D., et al. (2012). The
mechanism of lipofectamine 2000 mediated transmembrane gene delivery.
Engineering 5, 172–175. doi: 10.4236/eng.2012.410B045
Desai, P., and Person, S. (1998). Incorporation of the green fluorescent protein into
the herpes simplex virus type 1 capsid. J. Virol. 72, 7563–7568.
Dollery, S. J., Delboy, M. G., and Nicola, A. V. (2010). Low pH-induced
conformational change in herpes simplex virus glycoprotein B. J. Virol. 84,
3759–3766. doi: 10.1128/JVI.02573-09
Ferro, V. (2013). Heparan sulfate inhibitors and their therapeutic implications
in inflammatory illnesses. Expert Opin. Ther. Targets. 17, 965–975. doi:
10.1517/14728222.2013.811491
Geisow, M. J., and Evans, W. H. (1984). pH in the endosome. Measurements
during pinocytosis and receptor-mediated endocytosis. Exp. Cell Res. 150,
36–46. doi: 10.1016/0014-4827(84)90699-2
Geraghty, R. J., Krummenacher, C., Cohen, G. H., Eisenberg, R. J., and Spear,
P. G. (1998). Entry of alphaherpesviruses mediated by poliovirus receptor-
related protein 1 and poliovirus receptor. Science 280, 1618–1620. doi:
10.1126/science.280.5369.1618
Heine, J. W., Honess, R. W., Cassai, E., and Roizman, B. (1974). Proteins specified
by herpes simplex virus. XII. The virion polypeptides of type 1 strains. J. Virol.
14, 640–651.
Herold, B. C., WuDunn, D., Soltys, N., and Spear, P. G. (1991). Glycoprotein C of
herpes simplex virus type 1 plays a principal role in the adsorption of virus to
cells and in infectivity. J. Virol. 65, 1090–1098.
Innes, C. L., Smith, P. B., Langenbach, R., Tindall, K. R., and Boone, L. R. (1990).
Cationic liposomes (Lipofectin) mediate retroviral infection in the absence of
specific receptors. J. Virol. 64, 957–961.
Johnson, D. C., Wisner, T. W., and Wright, C. C. (2011). Herpes simplex virus
glycoproteins gB and gD function in a redundant fashion to promote secondary
envelopment. J. Virol. 85, 4910–4926. doi: 10.1128/JVI.00011-11
Johnson, D. C., and Baines, J. D. (2011). Herpesviruses remodel host membranes
for virus egress. Nat. Rev. Micro. 9, 382–394. doi: 10.1038/nrmicro2559
Karasneh, G. A., and Shukla, D. (2011). Herpes simplex virus infects most cell types
in vitro: clues to its success. Virol. J. 8:481. doi: 10.1186/1743-422X-8-481
Lukacs, G. L., Rotstein, O. D., and Grinstein, S. (1990). Phagosomal acidification
is mediated by a vacuolar-type H(+)-ATPase in murine macrophages. J. Biol.
Chem. 265, 21099–21107.
Lyman, M. G., and Enquist, L. W. (2009). Herpesvirus interaction with the host
cytoskeleton. J. Virol. 83, 2058–2066. doi: 10.1128/JVI.01718-08
Montgomery, R. I., Warner, M. S., Lum, B. J., and Spear, P. G. (1996). Herpes
simplex virus-1 entry into cells mediated by a novel member of the TNF/NGF
receptor family. Cell 87, 427–436. doi: 10.1016/S0092-8674(00)81363-X
Nahmias, A. J., and Roizman, B. (1973). Infection with herpes-simplex viruses 1
and 2. II. N. Engl. J. Med. 289, 719–725. doi: 10.1056/NEJM197310042891404
Nicola, A. V., McEvoy, A. M., and Straus, S. E. (2003). Roles for endocytosis and
low pH in herpes simplex virus entry into HeLa and Chinese hamster ovary
cells. J. Virol. 77, 5324–5332. doi: 10.1128/JVI.77.9.5324-5332.2003
Oh, M. J., Akhtar, J., Desai, P., and Shukla, D. A. (2010). Role for heparan
sulfate in viral surfing. Biochem. Biophys. Res. Commun. 391, 176–181. doi:
10.1016/j.bbrc.2009.11.027
Pertel, P. E., Fridberg, A., Parish, M. L., and Spear, P. G. (2001). Cell fusion
induced by herpes simplex virus glycoproteins gB, gD, and gH-gL requires a
gD receptor but not necessarily heparan sulfate. Virology 279, 313–324. doi:
10.1006/viro.2000.0713
Salameh, S., Sheth, U., and Shukla, D. (2012). Early events in herpes simplex virus
lifecycle with implications for an infection of lifetime. Open Virol. J. 6, 1–6. doi:
10.2174/1874357901206010001
Shieh, M. T., WuDunn, D., Montgomery, R. I., Esko, J. D., and Spear, P. G.
(1992). Cell surface receptors for herpes simplex virus are heparan sulfate
proteoglycans. J. Cell Biol. 116, 1273–1281. doi: 10.1083/jcb.116.5.1273
Shukla, D., Liu, J., Blaiklock, P., Shworak, N. W., Bai, X., Esko, J. D., et al. (1999). A
novel role for 3-O-sulfated heparan sulfate in herpes simplex virus 1 entry. Cell
99, 13–22. doi: 10.1016/S0092-8674(00)80058-6
Shukla, D., and Spear, P. G. (2001). Herpesviruses and heparan sulfate: an
intimate relationship in aid of viral entry. J. Clin. Invest. 108, 503–510. doi:
10.1172/JCI200113799
Spear, P. G., and Longnecker, R. (2003). Herpesvirus entry: an update. Virol 77,
10179–10185. doi: 10.1128/JVI.77.19.10179-10185.2003
Tiwari, V., Clement, C., Xu, D., Valyi-Nagy, T., Yue, B. Y., Liu, J., et al. (2006). Role
for 3-O-sulfated heparan sulfate as the receptor for herpes simplex virus type
Frontiers in Microbiology | www.frontiersin.org 9 June 2016 | Volume 7 | Article 973
Burnham et al. HSV Entry in Presence of Lipofectamine
1 entry into primary human corneal fibroblasts. J. Virol. 80, 8970–8980. doi:
10.1128/JVI.00296-06
Weinheimer, S. P., Boyd, B. A., Durham, S. K., Resnick, J. L., and O’Boyle, D. R.
(1992). Deletion of the VP16 open reading frame of herpes simplex virus type
1. J. Virol. 66, 258–269.
Whitley, R. J., Kimberlin, D. W., and Roizman, B. (1998). Herpes simplex viruses.
Clin. Infect. Dis. 26, 541–553. doi: 10.1086/514600
Whitley, R. J., and Roizman, B. (2001). Herpes simplex virus infections. Lancet 357,
1513–1518. doi: 10.1016/S0140-6736(00)04638-9
WuDunn, D., and Spear, P. G. (1989). Initial interaction of herpes simplex virus
with cells is binding to heparan sulfate. J. Virol. 63, 52–58.
Conflict of Interest Statement: The authors declare that the research was
conducted in the absence of any commercial or financial relationships that could
be construed as a potential conflict of interest.
Copyright © 2016 Burnham, Jaishankar, Thompson, Jones, Shukla and Tiwari. This
is an open-access article distributed under the terms of the Creative Commons
Attribution License (CC BY). The use, distribution or reproduction in other forums
is permitted, provided the original author(s) or licensor are credited and that the
original publication in this journal is cited, in accordance with accepted academic
practice. No use, distribution or reproduction is permitted which does not comply
with these terms.
Frontiers in Microbiology | www.frontiersin.org 10 June 2016 | Volume 7 | Article 973
